Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 2/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14350243 | 0.84 | CHRM1 (0.47) | LMNACHRM1NOTUMKDM4EALDH1A1 | |
| SCHEMBL23667424 | 0.84 | CHRM1 (0.47) | LMNACHRM1NOTUMKDM4EALDH1A1 | |
| SCHEMBL6881146 | 0.84 | CHRM1 (0.47) | LMNACHRM1NOTUMKDM4EALDH1A1 | |
| SCHEMBL14350215 | 0.84 | NOTUM (0.49) | LMNACHRM1NOTUMKDM4EALDH1A1 | |
| SCHEMBL18865832 | 0.81 | NOTUM (0.53) | LMNANOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL29691050 | 0.81 | NOTUM (0.53) | LMNANOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL7091177 | 0.81 | LMNA (0.44) | LMNACHRM1NOTUMKDM4EALDH1A1 | |
| SCHEMBL14350205 | 0.81 | CHRM1 (0.47) | LMNACHRM1NOTUMKDM4EALDH1A1 | |
| SCHEMBL3103821 | 0.80 | NOTUM (0.58) | LMNACHRM1NOTUMKDM4EALDH1A1 | |
| SCHEMBL23532735 | 0.79 | MPO (0.46) | LMNACHRM1NOTUMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20220281869-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| CN-114702495-A | Purinones as ubiquitin-specific protease 1 inhibitors | 福马治疗有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-108473495-B | Purinones as ubiquitin-specific protease 1 inhibitors | 福马治疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3696181-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3696181-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10189841-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189841-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180339986-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-11-29 | — | — | US | disclosed |
| EP-3377493-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20180118746-A1 | SUBSTITUTED IMIDAZOPYRIDINE AND TRIAZOLOPYRIDINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2018-05-03 | — | — | US | disclosed |
| US-20180118746-A1 | SUBSTITUTED IMIDAZOPYRIDINE AND TRIAZOLOPYRIDINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2018-05-03 | — | — | US | disclosed |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| WO-2016172547-A1 | SUBSTITUTED IMIDAZOPYRIDINE AND TRIAZOLOPYRIDINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY (US) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | LMNA 2181/4885CHRM1 1340/4885NOTUM 4073/4885 |
| US-20180339986-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | LMNA 2181/4885CHRM1 1340/4885NOTUM 4073/4885 |
| US-10189841-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | LMNA 2181/4885CHRM1 1340/4885NOTUM 4073/4885 |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | LMNA 2181/4885CHRM1 1340/4885NOTUM 4073/4885 |
| US-20220281869-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | LMNA 2181/4885CHRM1 1340/4885NOTUM 4073/4885 |
| US-20180118746-A1 | SUBSTITUTED IMIDAZOPYRIDINE AND TRIAZOLOPYRIDINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM5, CHRM4 | LMNA 4547/4885CHRM1 1/4885NOTUM 3052/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | LMNA 2181/4885CHRM1 1340/4885NOTUM 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.